Kalydeco (ivacaftor) Disease Interactions
There are 3 disease interactions with Kalydeco (ivacaftor):
Ivacaftor (Includes Kalydeco) ↔ cataracts
Moderate Potential Hazard, Moderate plausibility. Applies to: Cataracts
Cases of non- congenital lens opacities or cataracts have been reported in pediatric patients treated with ivacaftor, and although other risk factors could be present in some cases, a possible risk attributable to this medication cannot be excluded. Baseline and ophthalmological examinations are recommended in pediatric patients initiating treatment. Caution is advised in patients with ophthalmologic conditions.
Ivacaftor (Includes Kalydeco) ↔ hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Elevated transaminases have been reported in patients with cystic fibrosis receiving ivacaftor. It is recommended that liver function tests are assessed prior to treatment, every 3 months during the first year, and annually thereafter. Patients with increased levels should be closely monitored until the abnormalities resolve, and dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN). In patients with hepatic impairment, no dose adjustment is necessary in patients with mild impairment, but a reduced dose of ivacaftor is recommended in patients with moderate impairment (see prescribing information for dosing recommendations). Studies have not been conducted in patients with severe hepatic impairment, but exposure is expected to be higher than in patients with moderate impairment. Therefore, caution should be used on these patients, and a reduced dose is recommended after weighing the risks and benefits of treatment.
Ivacaftor (Includes Kalydeco) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
Ivacaftor has not been studied in patients with renal impairment. No dose adjustment is necessary for patients with mild or moderate renal impairment, however, caution is recommended in patients with severe renal impairment or end-stage renal disease.
Kalydeco (ivacaftor) drug interactions
There are 369 drug interactions with Kalydeco (ivacaftor)
Kalydeco (ivacaftor) alcohol/food interactions
There is 1 alcohol/food interaction with Kalydeco (ivacaftor)
More about Kalydeco (ivacaftor)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Drug class: CFTR potentiators
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.